Intravenous Nicorandil in STEMI Patients Undergoing Primary PCI: Insights from the CLEAN Randomized Clinical Trial and Broader Evidence

Intravenous Nicorandil in STEMI Patients Undergoing Primary PCI: Insights from the CLEAN Randomized Clinical Trial and Broader Evidence

The CLEAN trial shows intravenous nicorandil adjunctive to primary PCI does not significantly improve 12-month clinical outcomes in STEMI. Evidence suggests microvascular benefits but no consistent long-term mortality or infarct size reduction, challenging routine use in unselected patients.
Economic Evaluation of Thyroid Radiofrequency Ablation Versus Hemithyroidectomy: A Micro-Costing Perspective in Canadian Healthcare Settings

Economic Evaluation of Thyroid Radiofrequency Ablation Versus Hemithyroidectomy: A Micro-Costing Perspective in Canadian Healthcare Settings

This study quantitatively compares the direct healthcare costs of thyroid radiofrequency ablation (RFA) and hemithyroidectomy over one year, revealing cost advantages of RFA driven by reduced facility use, tempered by factors like repeat procedures and potential delayed surgeries.